New drug combo aims to tame kidney disease
NCT ID NCT07038382
First seen Nov 18, 2025 · Last updated May 20, 2026 · Updated 20 times
Summary
This study tests a new drug (HLX79) combined with an existing antibody treatment (rituximab) in people with active kidney inflammation called glomerulonephritis. The goal is to see if the combination is safe and helps control the disease better than rituximab alone. About 24 adults with membranous nephropathy or lupus nephritis will receive different doses of HLX79 or a placebo, plus rituximab, and be followed for up to 48 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tsinghua Changgung Hospital
NOT_YET_RECRUITINGBeijing, China
-
Guangdong Provincial People's Hospital
NOT_YET_RECRUITINGGuangzhou, China
-
Jiangsu Province Hospital
NOT_YET_RECRUITINGNanjing, China
-
Jiangxi Provincial People's Hospital
NOT_YET_RECRUITINGNanchang, China
-
Peking University People's Hospital
NOT_YET_RECRUITINGBeijing, China
-
Renmin Hospital Of Wuhan University
NOT_YET_RECRUITINGWuhan, China
-
Shanghai General Hospital
RECRUITINGShanghai, China
-
Su Bei People's Hospital
NOT_YET_RECRUITINGYangzhou, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
NOT_YET_RECRUITINGGuangzhou, China
-
The First Affiliated Hospital Of Xiamen University
NOT_YET_RECRUITINGXiamen, China
-
The First Affiliated Hospital Zhejiang University School Of Medicine
NOT_YET_RECRUITINGHangzhou, China
-
The First Affiliated Hospital of Henan University of Science and Technology
NOT_YET_RECRUITINGLuoyang, China
-
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITINGNanchang, China
-
The First Affiliated Hospital of Xi'an Jiao Tong University
NOT_YET_RECRUITINGXi'an, China
-
The Second Hospital of Anhui Medical University
NOT_YET_RECRUITINGHefei, China
-
Xiangya Hospital Of Gentral South University
NOT_YET_RECRUITINGChangsha, China
-
Zhongdong Hospital Southeast University
NOT_YET_RECRUITINGNanjing, China
Conditions
Explore the condition pages connected to this study.